Link Cell Therapies (“Link”), an oncology cell therapy company, today announced its official launch from stealth with a $60 million Series A financing that was led by Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc., with participation from founding investors Samsara BioCapital and Sheatree Capital, as well as Wing Venture Capital and other new strategic and financial investors.
Link’s proprietary logic-gating technologies allow for safe targeting of multiple antigens that are co-expressed on cancer cells but do not overlap or only minimally overlap in their normal healthy tissue expression. This platform enables the creation of next-generation CAR-T therapeutics for solid and liquid cancers built upon an entirely new landscape of “clean” target pairs.
Read More – LI.FI Raises $29M in Series A Extension
“We recognized that for most cancer types, particularly solid tumors, the promise of CAR-T therapies is limited by a dearth of cancer-specific targets and abundant expression of most solid tumor targets in normal vital tissue,” said Co-Founder Robbie Majzner, MD of the Dana-Farber Cancer Institute and Harvard Medical School. “Link is advancing a technology that we developed while at Stanford University that allows for logic- gated CAR-T cell control. The Link-based CAR activates and kills target cells only when a combination of antigens is co-localized on the tumor, thereby bypassing normal tissues that express only one of those targets. We believe this approach will enable potent CAR-T therapies to attack a wide range of tumors while sparing healthy tissue.”
Link Cell Therapies Announces $92 Million Raised Across Seed and Series A Financings The Series A financing, which follows a 2022 Seed Round led by Samsara and Sheatree, adds a number of strong financial and strategic investors to the syndicate, including JJDC, Inc, Bristol Myers Squibb, Kyowa Kirin, Wing Venture Capital, and Sherpa Healthcare Partners.
Read More – Chai Discovery Raises $130M in Series B Funding
